TeraPore Technologies, a developer of advanced nanofiltration membrane systems for biomanufacturing, announced today that it has raised $10 million in new capital. The round was led by existing investor Anzu Partners, with participation from Entegris, a global leader in advanced materials science, and RA Capital Management, another existing investor. TeraPore will use the funds to launch its IsoBlockTM virus filter and expand its core technology’s use into new high-value markets.
TeraPore is creating a new generation of high-capacity, high-yield bioseparation solutions that allow for controllable, consistent purification processes in the production of novel therapeutics and biologics.
The IsoBlock virus filters are purpose-built to provide superior filter productivity and robust viral clearance during process development, clinical trials, and production scale manufacturing. The company is creating an IsoBlock filter family with various properties and device sizes.
Mani Krishnan, a seasoned expert in the filtration and biotechnology sector who held leadership roles at Millipore Sigma and Pall Corporation, will also join the TeraPore Board of Directors.
TeraPore Technologies creates membrane nanofiltration systems with high permeability and resolution for bioprocessing and other applications. Its goal is to solve the most difficult bioseparation problems.
